Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Product information and disease descriptionProduct descriptionProduct information

Contraindications/Warnings/Precautions/Adverse effects

29 evidence topics · 17 sources

Warnings and precautions
FDA-approved prescribing information for Barzolvolimab

Not applicable.

Adverse events through the Week 24 placebo-controlled period: pooled EMBARQ-CSU1 and EMBARQ-CSU2
Adverse event, n (%)Placebo Q4WBarzolvolimab 150 mg Q4WBarzolvolimab 300 mg Q8W
Participants (N)“N=645”“N=648”“N=641”
Participants with at least 1 adverse event“340 (52.7)”“490 (75.6)”“492 (76.8)”
Hair color changes“29 (4.5)”“292 (45.1)”“330 (51.5)”
Skin hypopigmentation“16 (2.5)”“71 (11.0)”“64 (10.0)”
Neutropenia“4 (0.6)”“59 (9.1)”“75 (11.7)”
Skin hyperpigmentation“5 (0.8)”“59 (9.1)”“58 (9.1)”
Dysgeusia“9 (1.4)”“44 (6.8)”“63 (9.8)”
Hypogeusia“10 (1.6)”“33 (5.1)”“53 (8.3)”
Nasopharyngitis“36 (5.6)”“41 (6.3)”“40 (6.2)”
Anemia“4 (0.6)”“20 (3.1)”“20 (3.1)”
Participants with serious adverse events“15 (2.3)”“6 (0.9)”“14 (2.2)”
Treatment-related serious adverse events“1 (0.2)”“3 (0.5)”“4 (0.6)”
Hematologic laboratory decreases: phase 1b intravenous dosing in chronic spontaneous urticaria

“This Phase 1b, randomized, double‐blinded, placebo‐controlled study (NCT04538794) in patients with CSU refractory to antihistamines assessed barzolvolimab safety, PK, and PD compared with placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients were randomly assigned in a 4:1 ratio to receive a 60‐min intravenous infusion of either barzolvolimab or placebo (saline) Q4W or Q8W according to their assigned cohort (1: 0.5 mg/kg Q4W; 2: 1.5 mg/kg Q4W; 3: 3.0 mg/kg Q8W; and 4: 4.5 mg/kg Q8W) over 12 weeks” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Decreases in leukocytes, absolute neutrophil count, hemoglobin, and platelets were observed in patients after the first barzolvolimab dose when compared with placebo; no additional decreases were observed after subsequent doses (Figure S3). The majority of shifts were to Grades 1 and 2. A patient who received 4.5‐mg/kg barzolvolimab experienced a Grade 3 decrease in platelets; there was one patient also in the 4.5‐mg/kg group who experienced a Grade 2 decrease in WBC and did not receive the second dose per protocol; and three patients experienced Grade 3 decreased neutrophils (one in the 1.5‐mg/kg group and two in the 4.5‐mg/kg group); these all resolved during the study. There was no correlation of decreases with dose level. There were no trends of neutropenia correlating with increased infections.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The most common AE related to treatment with barzolvolimab was mild hair color changes, followed by mild‐to‐moderate neutropenia, which was not associated with infections. Decreases in hematologic parameters were consistent with observations in healthy volunteers [10] and patients with chronic inducible urticaria [7] who received a single barzolvolimab dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Hair color and skin pigmentation changes: phase 2 through Week 76

“The objective of this analysis was to assess the rate and reversibility of pigmentation changes over 76 weeks in patients with CSU treated with barzolvolimab” (opens the source at this quote in a new tab)

“204 patients received ≥1 dose of barzolvolimab (any dose) and were included in this analysis” (opens the source at this quote in a new tab)

“Hair color changes (hypopigmentation) occurred in 49 (24%) patients; 96% of hair color changes were mild (Grade 1). Mean time to onset was ≈4 months, with 91% of evaluable patients reporting resolution of hair color change by the end of study participation” (opens the source at this quote in a new tab)

“Skin hypopigmentation occurred in 36 (18%) patients and events were mostly mild (94%; Grade 1); mean onset was ≈9 months, with 68% of evaluable patients reporting resolution by data cutoff” (opens the source at this quote in a new tab)

“Skin hyperpigmentation occurred in 6 (3%) patients, all of whom reported the events as mild (Grade 1); mean time to onset was ≈5 months, with 67% of evaluable patients reporting resolution by data cutoff” (opens the source at this quote in a new tab)

“Overall, 19 (9%) of patients reported concomitant hair color changes and skin hypopigmentation; 4 (2%) reported hair color changes and concomitant skin hyperpigmentation” (opens the source at this quote in a new tab)

“KIT-mediated hair color and skin pigmentation changes were observed in a subset of patients and were generally mild and reversible” (opens the source at this quote in a new tab)

CharacteristicHair color changesSkin hypopigmentationSkin hyperpigmentation
Participants with the event“n=49”“n=36”“n=6”
Grade 1, n (%)“47 (96)”“34 (94)”“6 (100)”
Time to onset from start of barzolvolimab, days, mean (range)“137 (7-397)”“271 (107-424)”“156 (11-283)”
Resolved at the time of data cutoff, n (%)“40 (91)”“19 (68)”“4 (67)”
Time to resolution on treatment, days, median (95% CI)“209 (119, 231)”“110 (60, 120)”“25 (7, NE)”
Time to resolution off treatment, days, median (95% CI)“168 (138,189)”“214 (196, 285)”“NE”
Discontinued study treatment due to event, n (%)“6 (3)”“0 (0)”“1 (<0.5)”
Phase 2 adverse events: placebo-controlled period to Week 16 and treatment period to Week 52
Participants, n (%)Barzolvolimab, all doses, Weeks 0 to 16Placebo, Weeks 0 to 16Barzolvolimab, all doses, Weeks 0 to 52Placebo then barzolvolimab, 36 weeks of barzolvolimab
Participants (N)“N= 156”“N= 51”“N= 156”“N=48”
At least one adverse event“103 (66)”“20 (39)”“139 (89)”“32 (67)”
Treatment-related serious adverse events“0”“0”“2 (1)”“0”
Hair color changes“22 (14)”“0”“40 (26)”“8 (17)”
Neutropenia or neutrophil count decreased“14 (9)”“0”“26 (17)”“2 (4)”
Urticaria“15 (10)”“5 (10)”“23 (15)”“3 (6)”
Skin hypopigmentation“2 (1)”“0”“21 (13)”“9 (19)”
Nasopharyngitis“6 (4)”“3 (6)”“15 (10)”“4 (8)”
Phase 1b adverse events at 24 weeks: intravenous dosing in chronic spontaneous urticaria
Chronic inducible urticaria phase 1b: single 3 mg/kg intravenous dose

“This is an ongoing single center, open-label Phase 1b study evaluating the safety/tolerability and clinical efficacy of a single dose of barzolvolimab in patients with CIndU refractory to SG-H1AHs.” (opens the source at this quote in a new tab)

“Single dose of barzolvolimab is administered intravenously on Day 1, and patients are followed for 12 weeks for safety, PD, and clinical activity assessments.” (opens the source at this quote in a new tab)

“Here, we report data from two cohorts of patients with ColdU and SD treated with a single dose of barzolvolimab (3 mg/kg) followed for 12 weeks as detailed below.” (opens the source at this quote in a new tab)

“Barzolvolimab was well tolerated (Table 2). All 21 patients reported AE. Most AEs were mild, and the most common (≥3 patients) were hair color changes (areas of hair lightening) (76%; n = 16/21), infusion reactions (43%; n = 9/21), taste changes (38%; n = 8/21), nasopharyngitis (24%; n = 5/21), malaise (24%; n = 5/21), and headache (19%; n = 4/21).” (opens the source at this quote in a new tab)

“Infusion reactions, which manifested as localized hives and itching as well as erythema and feeling hot, resolved spontaneously. One patient with a history of fainting experienced loss of consciousness during infusion; this event was not associated with MC activation based on decreasing tryptase values shortly after the event.” (opens the source at this quote in a new tab)

“Overall, mean hematology parameters remained within the normal ranges. Mild, transient, and asymptomatic decreases in hemoglobin and white blood cell parameters occurred for some patients (Figure S1).” (opens the source at this quote in a new tab)

Chronic inducible urticaria phase 2: Week 12 and Week 20 treatment periods

“We completed a Phase 2 study in patients with CIndU who remain symptomatic despite antihistamine therapy.” (opens the source at this quote in a new tab)

“Barzolvolimab was well tolerated with a favorable safety profile consistent with prior studies. Most adverse events were grade 1 (mild). Through 12 weeks, the most common treatment emergent adverse events in barzolvolimab treated patients were hair color changes (13%; Grade 1, n=15 / Grade 2, n=2) and neutropenia (10%; Grade 1, n=7 / Grade 2, n=6), which are mechanism related (KIT) and expected to be reversible. The rate of infections was similar between barzolvolimab-treated patients and placebo with no association between neutropenia and infections.” (opens the source at this quote in a new tab)

“Barzolvolimab was well tolerated with a favorable safety profile over the 20 week treatment period consistent with previous studies. There was no difference between active treatment (2%) and placebo groups (3%) in rate of discontinuations due to adverse events. Most adverse events for patients on study drug were grade 1 (mild), mechanism related (KIT) and, as demonstrated in previous studies, expected to be reversible. The most common adverse events occurring in greater than 10% of patients in any treatment group through Week 20 were hair color changes (18%; Grade 1, n=22 / Grade 2, n=2) and neutropenia (12%; Grade 1, n=9 / Grade 2, n=6). Neutropenia was transient and there was no association with infections.” (opens the source at this quote in a new tab)

Participants, n (%)Barzolvolimab 150 mg Q4WBarzolvolimab 300 mg Q8WAll barzolvolimabPlacebo
Participants (n)“n=65”“n=65”“n=130”“n=63”
Any adverse event“40 (62%)”“39 (60%)”“79 (61%)”“33 (52%)”
Treatment-related serious adverse events“0”“1 (2%)”“1 (1%)”“0”
Discontinued study treatment for adverse events“1 (2%)”“2 (3%)”“3 (2%)”“2 (3%)”
Hair color changes“9 (14%)”“8 (12%)”“17 (13%)”“0”
Neutropenia“4 (6%)”“9 (14%)”“13 (10%)”“0”
Healthy volunteers: single intravenous doses of 0.3 to 9 mg/kg

“placebo‐controlled phase 1a healthy volunteer study of CDX‐0159” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A single dose of CDX‐0159 at 0.3, 1, 3, and 9 mg/kg, or placebo was intravenously administered to healthy subjects (Table 1). A CDX‐0159 intravenous infusion was well tolerated at all doses. The most common adverse event (AE)s observed in thirteen out of twenty‐four subjects who received CDX‐0159 were mild, self‐limited infusion reactions that were consistently described as areas of local itching associated with erythema, and induration/hives, which started during the infusions (Table 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Mild decreases in hemoglobin levels generally within the normal range were observed, which rapidly stabilized despite the presence of high plasma drug levels (Figure 3A).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In addition, all CDX‐0159 treatment groups showed variable, asymptomatic decreases relative to placebo on circulating neutrophils, which were also reflected in the total leukocyte count and did not further decline during the course of the study (Figure 3B,C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In our healthy volunteer study, there were no reports of hair color changes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote